A Welcome Message From KoSAR’s Leadership Team

Thank you for visiting the Korean Severe Asthma Registry (KoSAR) website.

While severe asthma accounts for approximately 5-10% of all asthma, it is associated with more frequent medical visits, higher medications, increased morbidity and mortality, and significant economic burden.

The Working Group (WG) on Severe Asthma, the Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI), is committed to discovering and gathering the newest insights around managing patients with intractable asthma and the latest, most up-to-date treatment strategy available.

Since 2011, the WG has been operating the KoSAR, which is a multicenter real-world clinical observational study of severe asthma in Korea.

The KoSAR-2 study launched in 2022 and collects data on the clinical and pathophysiological characteristics of severe asthma patients. Using biometric information such as omics and CT imaging of the chest, we will evaluate the long-term prognosis of severe asthma through prospective and systematic follow-up. Through KoSAR, we hope to gain a better understanding of the factors that contribute to severe asthma and suggest a broader ranges of safe and effective treatment options.

We would like to express our deepest gratitude to the patients who took part in the KoSAR study.

This study will greatly help understand the clinical characteristics and diversity of severe asthma patients and establish better treatment strategies for severe asthma.

We look forward to your active participation and full support.

Thank you!

Sang-Heon Kim, MD, PhD
Chair, the Working Group on Severe Asthma, KAAACI